Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Nov. 09, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | CTD HOLDINGS INC | |
Entity Central Index Key | 922,247 | |
Trading Symbol | ctdh | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 73,105,834 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 1,342,642 | $ 960,197 |
Accounts receivable | 94,017 | 89,667 |
Inventory | 474,010 | 497,397 |
Current portion of mortgage note receivable | 34,393 | 34,393 |
Other | 20,210 | 53,879 |
Total current assets | 1,965,272 | 1,635,533 |
FURNITURE AND EQUIPMENT, NET | 27,225 | 29,984 |
Mortgage note receivable, less current portion | 177,359 | 203,028 |
TOTAL ASSETS | 2,169,856 | 1,868,545 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 545,171 | 342,542 |
Advance – private placement | 585,000 | |
Total current liabilities | 1,130,171 | 342,542 |
STOCKHOLDERS' EQUITY | ||
Common stock, par value $.0001 per share, 100,000,000 shares authorized, 72,999,361 and 66,952,529 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 7,299 | 6,695 |
Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, no shares issued or outstanding | ||
Additional paid-in capital | 12,980,986 | 11,018,915 |
Accumulated deficit | (11,948,600) | (9,499,607) |
Total stockholders' equity | 1,039,685 | 1,526,003 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 2,169,856 | $ 1,868,545 |
Consolidated Balance Sheets (C3
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2017 | Dec. 31, 2016 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 72,999,361 | 66,952,529 |
Common stock, shares outstanding (in shares) | 72,999,361 | 66,952,529 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, share authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
REVENUES | ||||
Product sales | $ 241,147 | $ 278,196 | $ 1,069,289 | $ 975,267 |
EXPENSES | ||||
Personnel | 268,684 | 327,858 | 908,049 | 1,010,296 |
Cost of products sold (exclusive of depreciation, shown separately below) | 19,660 | 30,893 | 118,056 | 123,896 |
Research and development | 338,723 | 311,351 | 1,509,352 | 1,254,900 |
Repairs and maintenance | 1,203 | 3,334 | 5,198 | 19,073 |
Professional fees | 116,004 | 175,616 | 542,007 | 454,646 |
Office and other | 111,713 | 171,425 | 338,250 | 478,740 |
Board of Director fees and costs | 18,010 | 53,195 | 94,763 | 99,576 |
Depreciation | 2,413 | 3,789 | 6,873 | 92,146 |
Freight and shipping | 1,635 | 1,465 | 6,246 | 5,257 |
Loss (gain) on sale of property and equipment | (1,261) | 4,489 | ||
Impairment on assets held for sale | 810,000 | 810,000 | ||
878,045 | 1,888,926 | 3,527,533 | 4,353,019 | |
LOSS FROM OPERATIONS | (636,898) | (1,610,730) | (2,458,244) | (3,377,752) |
OTHER INCOME (EXPENSE) | ||||
Investment and other income | 3,149 | 2,766 | 9,251 | 7,609 |
Interest expense | (6,969) | (21,722) | ||
3,149 | (4,203) | 9,251 | (14,113) | |
LOSS BEFORE INCOME TAXES | (633,749) | (1,614,933) | (2,448,993) | (3,391,865) |
Provision for income taxes | ||||
NET LOSS | $ (633,749) | $ (1,614,933) | $ (2,448,993) | $ (3,391,865) |
BASIC AND FULLY DILUTED NET LOSS PER COMMON SHARE (in dollars per share) | $ (0.01) | $ (0.02) | $ (0.03) | $ (0.05) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares) | 72,966,028 | 66,889,822 | 71,721,264 | 62,121,283 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (2,448,993) | $ (3,391,865) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 6,873 | 92,146 |
Loss (gain) on sale of property and equipment | (1,261) | 4,489 |
Impairment on assets held for sale | 810,000 | |
Accrued stock compensation to employees | 76,030 | 57,114 |
Accrued stock compensation to non-employees | 31,110 | 44,106 |
Increase or decrease in: | ||
Accounts receivable | (4,350) | (68,598) |
Inventory | 23,387 | 19,758 |
Other current assets | 33,669 | 13,173 |
Accounts payable and accrued expenses | 207,109 | 33,120 |
Total adjustments | 372,567 | 1,005,308 |
NET CASH USED IN OPERATING ACTIVITIES | (2,076,426) | (2,386,557) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Purchase of equipment and building improvements | (7,503) | (9,343) |
Proceeds from mortgage note receivable | 25,669 | 19,203 |
Proceeds from sale of equipment | 4,650 | 5,510 |
NET CASH PROVIDED BY INVESTING ACTIVITIES | 22,816 | 15,370 |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from Issuance of Private Placement | 585,000 | |
Net proceeds from sale of common stock and warrants | 1,851,055 | 1,880,000 |
Principal payments on notes payable | (46,704) | |
Payments on line of credit | (34,296) | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,436,055 | 1,799,000 |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 382,445 | (572,187) |
CASH AND CASH EQUIVALENTS, beginning of period | 960,197 | 1,842,233 |
CASH AND CASH EQUIVALENTS, end of period | 1,342,642 | 1,270,046 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
Cash paid for interest | 21,722 | |
Cash paid for income taxes | ||
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING | ||
Exchange of property held for sale for a mortgage note receivable | $ 265,000 |
Note 1 - Summary of Significant
Note 1 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | ( 1 The following is a summary of the more significant accounting policies of CTD Holdings, Inc. and subsidiaries ( “we”, “our”, “us” or the “Company”) that affect the accompanying consolidated financial statements. (a) ORGANIZATION AND OPERATIONS ––The Company was incorporated in August 1990, July 1992. rare and fatal cholesterol metabolism disease that impacts the brain, lung, liver, spleen, and other organs. The FDA recently approved our Investigational New Drug application (IND) which describes our Phase I clinical plans in the U.S. for Trappsol® Cyclo™ and in January 2017 1 September 2017. first July 2017. We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs with continuing growth in research and new product development. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. (b) BASIS OF PRESENTATION ––The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10 10 01 X. not Operating results for the three nine September 30, 2017 not may December 31, 2017. 10 December 31, 2016, March 17, 2017. (c) CASH AND CASH EQUIVALENTS ––Cash and cash equivalents consist of cash and any highly liquid investments with an original maturity of three (d) ACCOUNTS RECEIVABLE ––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Based on our assessment of the credit history with customers having outstanding balances and current relationships with them, we have concluded that losses on balances outstanding at September 30, 2017 December 31, 2016 (e) INVENTORY AND COST OF PRODUCTS SOLD ––Inventory consists of our pharmaceutical drug Trappsol® Cyclo™, cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost ( first first not (f) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost. Depreciation on furniture and equipment is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten (g) REVENUE RECOGNITION ––We recognize revenue from product sales, and royalties when the following four four no September 30, 2017 December 31, 2016. (h) RESEARCH AND DEVELOPMENT COSTS ––Research and development costs are expensed as incurred. (i) INCOME TAXES ––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% (j) NET LOSS PER COMMON SHARE ––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented; outstanding warrants to purchase 15,085,787 9,057,500 three nine September 30, 2017 2016, (k) STOCK BASED COMPENSATION ––The Company periodically awards stock to employees, directors, and consultants. An expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. (l) CONCENTRATIONS OF CREDIT RISK ––Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: (i) DEMAND AND CERTIFICATE OF DEPOSITS ––We maintain bank accounts in Federal credit unions and other financial institutions, which are insured up to the Federal Deposit Insurance Corporation limits. The bank accounts may not (ii) ACCOUNTS RECEIVABLE ––Our accounts receivable consist of amounts due primarily from chemical supply and pharmaceutical companies located primarily in the United States. Three 87% September 30, 2017. Two 81% December 31, 2016. no (m) LIQUIDITY ––For the year ended December 31, 2016, $4,223,841 $2,950,938 December 31, 2016, $960,197 $1,292,991. nine September 30, 2017, $2,448,993 $2,076,426. September 30, 2017, $1,342,642 $585,000 October 2017) $1,420,101. October 2017, $1,465,000, $585,000 September 2017, November 2018 may (n) USE OF ESTIMATES ––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. (o) RECLASSIFICATIONS – Certain amounts in the 2016 2017 no ( p) NEW ACCOUNTING PRONOUNCEMENTS––The Financial Accounting Standards Board (FASB) has issued various Accounting Standards Updates (ASUs), including ASU 2014 09, 2015 17, 2016 02, not |
Note 2 - Mortgage Note Receivab
Note 2 - Mortgage Note Receivable | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | ( 2 On January 21, 2016, $275,000. $10,000 $265,000, ’s obligations under the promissory note. The promissory note provides for monthly payments of $3,653, 4.25%, seven March 1, 2016, February 2023 |
Note 3 - Equity Transactions
Note 3 - Equity Transactions | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | ( 3 ) EQUITY TRANSACTIONS: The Company expensed $61,720 $107,140 three nine September 30, 2017, 120,000 ion. The Company expensed $30,460 $101,220 three nine September 30, 2016, March 31, 2017, 172,000 $67,100 eight In October 2017, 15,250 $100 one 400 seven 400 $0.25 $100 not not September 30, 2017, $585,000 September 30, 2017, On February 23, 2017, 5,754,832 $0.35 one seven $0.35, $2 $153,000, seven 230,193 $0.35 As of September 30, 2017, 14,332,332 $0.25 $1.00 2024. seven September 30, 2017 710,193 $0.25 $0.35 |
Note 4 - Income Taxes
Note 4 - Income Taxes | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | ( 4 ) INCOME TAXES: The Company reported a net loss for the three nine September 30, 2017 2016, |
Note 5 - Sales Concentrations
Note 5 - Sales Concentrations | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | ( 5 ) SALES CONCENTRATIONS: Sales to two 59% 55% three nine September 30, 2017, two 51% 52% three nine September 30, 2016, one |
Note 6 - Subsequent Event
Note 6 - Subsequent Event | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | ( 6 I n October 2017, 3. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2017 | |
Accounting Policies [Abstract] | |
Organization and Operations [Policy Text Block] | (a) ORGANIZATION AND OPERATIONS ––The Company was incorporated in August 1990, July 1992. rare and fatal cholesterol metabolism disease that impacts the brain, lung, liver, spleen, and other organs. The FDA recently approved our Investigational New Drug application (IND) which describes our Phase I clinical plans in the U.S. for Trappsol® Cyclo™ and in January 2017 1 September 2017. first July 2017. We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs with continuing growth in research and new product development. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. |
Basis of Accounting, Policy [Policy Text Block] | (b) BASIS OF PRESENTATION ––The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10 10 01 X. not Operating results for the three nine September 30, 2017 not may December 31, 2017. 10 December 31, 2016, March 17, 2017. |
Cash and Cash Equivalents, Policy [Policy Text Block] | (c) CASH AND CASH EQUIVALENTS ––Cash and cash equivalents consist of cash and any highly liquid investments with an original maturity of three |
Receivables, Policy [Policy Text Block] | (d) ACCOUNTS RECEIVABLE ––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Based on our assessment of the credit history with customers having outstanding balances and current relationships with them, we have concluded that losses on balances outstanding at September 30, 2017 December 31, 2016 |
Inventory, Policy [Policy Text Block] | (e) INVENTORY AND COST OF PRODUCTS SOLD ––Inventory consists of our pharmaceutical drug Trappsol® Cyclo™, cyclodextrin products and chemical complexes purchased for resale recorded at the lower of cost ( first first not |
Property, Plant and Equipment, Policy [Policy Text Block] | (f) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost. Depreciation on furniture and equipment is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten |
Revenue Recognition, Policy [Policy Text Block] | (g) REVENUE RECOGNITION ––We recognize revenue from product sales, and royalties when the following four four no September 30, 2017 December 31, 2016. |
Research and Development Expense, Policy [Policy Text Block] | (h) RESEARCH AND DEVELOPMENT COSTS ––Research and development costs are expensed as incurred. |
Income Tax, Policy [Policy Text Block] | (i) INCOME TAXES ––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% |
Earnings Per Share, Policy [Policy Text Block] | (j) NET LOSS PER COMMON SHARE ––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented; outstanding warrants to purchase 15,085,787 9,057,500 three nine September 30, 2017 2016, |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | (k) STOCK BASED COMPENSATION ––The Company periodically awards stock to employees, directors, and consultants. An expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | (l) CONCENTRATIONS OF CREDIT RISK ––Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: (i) DEMAND AND CERTIFICATE OF DEPOSITS ––We maintain bank accounts in Federal credit unions and other financial institutions, which are insured up to the Federal Deposit Insurance Corporation limits. The bank accounts may not (ii) ACCOUNTS RECEIVABLE ––Our accounts receivable consist of amounts due primarily from chemical supply and pharmaceutical companies located primarily in the United States. Three 87% September 30, 2017. Two 81% December 31, 2016. no |
Liquidity [Policy Text Block] | (m) LIQUIDITY ––For the year ended December 31, 2016, $4,223,841 $2,950,938 December 31, 2016, $960,197 $1,292,991. nine September 30, 2017, $2,448,993 $2,076,426. September 30, 2017, $1,342,642 $585,000 October 2017) $1,420,101. October 2017, $1,465,000, $585,000 September 2017, November 2018 may |
Use of Estimates, Policy [Policy Text Block] | (n) USE OF ESTIMATES ––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. |
Reclassification, Policy [Policy Text Block] | (o) RECLASSIFICATIONS – Certain amounts in the 2016 2017 no |
New Accounting Pronouncements, Policy [Policy Text Block] | ( p) NEW ACCOUNTING PRONOUNCEMENTS––The Financial Accounting Standards Board (FASB) has issued various Accounting Standards Updates (ASUs), including ASU 2014 09, 2015 17, 2016 02, not |
Note 1 - Summary of Significa13
Note 1 - Summary of Significant Accounting Policies (Details Textual) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2017USD ($) | Oct. 31, 2017USD ($) | Sep. 30, 2017USD ($)shares | Sep. 30, 2016USD ($)shares | Sep. 30, 2017USD ($)shares | Sep. 30, 2016USD ($)shares | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Deferred Revenue | $ 0 | $ 0 | $ 0 | $ 0 | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 15,085,787 | 9,057,500 | 15,085,787 | 9,057,500 | ||||
Net Income (Loss) Attributable to Parent | $ (633,749) | $ (1,614,933) | $ (2,448,993) | $ (3,391,865) | (4,223,841) | |||
Net Cash Provided by (Used in) Operating Activities | (2,076,426) | (2,386,557) | (2,950,938) | |||||
Cash and Cash Equivalents, at Carrying Value | 1,342,642 | $ 1,342,642 | $ 1,270,046 | 1,342,642 | 1,270,046 | 960,197 | $ 1,842,233 | |
Working Capital | 1,420,101 | $ 1,292,991 | ||||||
Proceeds from Issuance of Private Placement | $ 585,000 | $ 1,465,000 | $ 585,000 | |||||
Accounts Receivable [Member] | ||||||||
Concentration Risk, Percentage | 87.00% | 81.00% | ||||||
Number of Customers Accounted | 3 | 2 | ||||||
Computers and Vehicles [Member] | Minimum [Member] | ||||||||
Property, Plant and Equipment, Useful Life | 3 years | |||||||
Computers and Vehicles [Member] | Maximum [Member] | ||||||||
Property, Plant and Equipment, Useful Life | 5 years | |||||||
Machinery and Furniture [Member] | Minimum [Member] | ||||||||
Property, Plant and Equipment, Useful Life | 7 years | |||||||
Machinery and Furniture [Member] | Maximum [Member] | ||||||||
Property, Plant and Equipment, Useful Life | 10 years |
Note 2 - Mortgage Note Receiv14
Note 2 - Mortgage Note Receivable (Details Textual) | Jan. 20, 2016USD ($) |
Real Estate Held-for-sale | $ 275,000 |
Proceeds from Sale of Property Held-for-sale | 10,000 |
Mortgage Loans on Real Estate, Face Amount of Mortgages | 265,000 |
Mortgage Loans on Real Estate, Monthly Payment | $ 3,653 |
Mortgage Loans on Real Estate, Interest Rate | 4.25% |
Note 3 - Equity Transactions (D
Note 3 - Equity Transactions (Details Textual) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Oct. 31, 2017$ / sharesshares | Sep. 30, 2017USD ($)$ / sharesshares | Feb. 23, 2017USD ($)$ / sharesshares | Oct. 31, 2017USD ($)$ / sharesshares | Sep. 30, 2017USD ($)$ / sharesshares | Mar. 31, 2017USD ($)shares | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)$ / sharesshares | Sep. 30, 2016USD ($) | |
Allocated Share-based Compensation Expense | $ | $ 61,720 | $ 30,460 | $ 107,140 | $ 101,220 | |||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares | 120,000 | ||||||||
Proceeds from Issuance of Private Placement | $ | $ 585,000 | $ 1,465,000 | $ 585,000 | ||||||
Warrant [Member] | |||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,000,000 | ||||||||
Term of Warrant | 7 years | 7 years | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.35 | ||||||||
Class of Warrant or Right, Outstanding | shares | 14,332,332 | 14,332,332 | 14,332,332 | ||||||
Warrant Expiration Date | 2,024 | ||||||||
Warrant [Member] | Minimum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.25 | $ 0.25 | $ 0.25 | ||||||
Warrant [Member] | Maximum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1 | $ 1 | $ 1 | ||||||
Warrant One [Member] | |||||||||
Class of Warrant or Right, Outstanding | shares | 710,193 | 710,193 | 710,193 | ||||||
Warrant One [Member] | Minimum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.25 | $ 0.25 | $ 0.25 | ||||||
Warrant One [Member] | Maximum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.35 | $ 0.35 | $ 0.35 | ||||||
Subsequent Event [Member] | Warrant [Member] | |||||||||
Term of Warrant | 7 years | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 400 | 400 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.25 | $ 0.25 | |||||||
Private Placement [Member] | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 5,754,832 | ||||||||
Share Price | $ / shares | $ 0.35 | ||||||||
Payment for Cash Fee | $ | $ 153,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares | 230,193 | ||||||||
Private Placement [Member] | Subsequent Event [Member] | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 15,250 | ||||||||
Share Price | $ / shares | $ 100 | $ 100 | |||||||
Private Placement [Member] | Subsequent Event [Member] | Series B Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion | shares | 400 | 400 | |||||||
Preferred Stock, Liquidation Preference Per Share | $ / shares | $ 100 | $ 100 | |||||||
Employee and Board [Member] | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 172,000 | ||||||||
Stock Issued During Period, Value, New Issues | $ | $ 67,100 | ||||||||
Number of Board | 8 |
Note 5 - Sales Concentrations (
Note 5 - Sales Concentrations (Details Textual) - Sales Concentrations [Member] - Customer Accounted [Member] | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Number of Major Customers Accounted for Accounts Receivable | 2 | 2 | ||
Concentration Risk, Percentage | 59.00% | 51.00% | 55.00% | 52.00% |